Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine in Modified Electroconvulsive Therapy for Depression
NCT04777110Phase 1Unknown
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, single-blind trial of esketamine in major depressive disorder (MDD) (2 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Relief rate of depressive symptoms after MECT treatment. Status: unknown.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04777110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04777110.